Renin-Angiotensin-Aldosterone Axis Inhibition Improves Outcome of Diabetic Patients with Chronic Hypertension and COVID-19: An Iranian Perspective.
ACE inhibitor
ARB
COVID-19
diabetes
hypertension
outcome
Journal
Advanced biomedical research
ISSN: 2277-9175
Titre abrégé: Adv Biomed Res
Pays: India
ID NLM: 101586897
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
06
2021
revised:
31
01
2022
accepted:
17
02
2022
entrez:
17
2
2023
pubmed:
18
2
2023
medline:
18
2
2023
Statut:
epublish
Résumé
Safe use of drugs such as angiotensin-converting enzyme 2 (ACE2) inhibitors and angiotensin receptor blockers (ARBs) in COVID diabetic patients needs comprehensive studies. This study addressed this issue from the Iranian perspective. Admitted COVID-19 patients were divided into four groups in this historical cohort study. Group 1 included 740 non-diabetic, non-hypertensive patients. Group 2 included 132 non-hypertensive diabetic patients. Group 3 included 154 non-diabetic hypertensive patients. Group 4 included 183 diabetic patients who were under ACE inhibitors or ARBs. Death, intensive care unit (ICU) admission, and length of hospitalization were compared between the groups. After considering associated factors such as age, gender, dyslipidemia, cardiovascular diseases, rheumatoid arthritis (RA), chronic kidney disease (CKD), history of surgery, and corticosteroid use, diabetic patients (group 2) were associated with increased mortality (CI 95%, OR 1.93 [1.11-3.33]). Presence of diabetes (group 2) and hypertension were associated with an increased need for ICU admission (CI 95%, OR 1.69 [1.04-2.76]; CI 95%, OR 1.71 [1.08-2.71], respectively). Group 4 patients although having a similar rate of ICU admission with group 2 and 3 patients, had significantly better ICU survival. The current study suggests that ACE inhibitors and ARBs are associated with decreased mortality, ICU admission, and better ICU survival in the diabetic subgroup of hypertensive patients.
Sections du résumé
Background
UNASSIGNED
Safe use of drugs such as angiotensin-converting enzyme 2 (ACE2) inhibitors and angiotensin receptor blockers (ARBs) in COVID diabetic patients needs comprehensive studies. This study addressed this issue from the Iranian perspective.
Materials and Methods
UNASSIGNED
Admitted COVID-19 patients were divided into four groups in this historical cohort study. Group 1 included 740 non-diabetic, non-hypertensive patients. Group 2 included 132 non-hypertensive diabetic patients. Group 3 included 154 non-diabetic hypertensive patients. Group 4 included 183 diabetic patients who were under ACE inhibitors or ARBs. Death, intensive care unit (ICU) admission, and length of hospitalization were compared between the groups.
Results
UNASSIGNED
After considering associated factors such as age, gender, dyslipidemia, cardiovascular diseases, rheumatoid arthritis (RA), chronic kidney disease (CKD), history of surgery, and corticosteroid use, diabetic patients (group 2) were associated with increased mortality (CI 95%, OR 1.93 [1.11-3.33]). Presence of diabetes (group 2) and hypertension were associated with an increased need for ICU admission (CI 95%, OR 1.69 [1.04-2.76]; CI 95%, OR 1.71 [1.08-2.71], respectively). Group 4 patients although having a similar rate of ICU admission with group 2 and 3 patients, had significantly better ICU survival.
Conclusions
UNASSIGNED
The current study suggests that ACE inhibitors and ARBs are associated with decreased mortality, ICU admission, and better ICU survival in the diabetic subgroup of hypertensive patients.
Identifiants
pubmed: 36798924
doi: 10.4103/abr.abr_177_21
pii: ABR-11-109
pmc: PMC9926032
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109Informations de copyright
Copyright: © 2022 Advanced Biomedical Research.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
Int J Biol Sci. 2018 Feb 12;14(3):253-265
pubmed: 29559844
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Diabetes Care. 2020 Jul;43(7):1382-1391
pubmed: 32409504
Nat Rev Nephrol. 2010 Jun;6(6):319-30
pubmed: 20440277
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026
pubmed: 32936273
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Eur Heart J. 2020 Jun 7;41(22):2058-2066
pubmed: 32498076
Hypertension. 2004 May;43(5):943-4
pubmed: 15007029
J Travel Med. 2020 May 18;27(3):
pubmed: 32186711
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
Travel Med Infect Dis. 2021 Mar-Apr;40:101995
pubmed: 33631340
Nat Commun. 2020 Oct 28;11(1):5453
pubmed: 33116139
New Microbes New Infect. 2021 Jul;42:100895
pubmed: 33976895
Am J Hypertens. 2015 Jan;28(1):15-21
pubmed: 24842388
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Radiology. 2020 Jun;295(3):200463
pubmed: 32077789
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014
pubmed: 32061198
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090
pubmed: 32228252
Hypertension. 2020 Jun;75(6):1382-1385
pubmed: 32208987
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Hypertension. 2020 Aug;76(2):366-372
pubmed: 32564693
Cell Transplant. 2015;24(9):1699-715
pubmed: 25291359
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1065-72
pubmed: 20581171
Amino Acids. 2015 Apr;47(4):693-705
pubmed: 25534429
J Am Heart Assoc. 2020 Apr 7;9(7):e016219
pubmed: 32233755
Clin Exp Pharmacol Physiol. 2010 Jan;37(1):e1-6
pubmed: 19793108
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 01;314(1):L17-L31
pubmed: 28935640
Endocr Pract. 2015 Apr;21(4):438-47
pubmed: 25877012
J Diabetes Sci Technol. 2020 Jul;14(4):813-821
pubmed: 32389027
Eur J Heart Fail. 2021 Mar;23(3):476-485
pubmed: 33222412
Circ Res. 2020 Jun 5;126(12):1671-1681
pubmed: 32302265
Health Sci Rep. 2021 Nov 17;4(4):e440
pubmed: 34869917
Hypertension. 2020 Jul;76(1):51-58
pubmed: 32348166